RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 New Monoclonal Antibody to PCSK9 Markedly Lowers LDL-C in Patients on Atorvastatin
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 4
SP 20
OP 21
DO 10.1177/155989771204014
UL http://mdc.sagepub.com/content/12/4/20.abstract
AB Proprotein convertase subtilisin/kexin type 9 serine protease (PCSK9) binds to low-density lipoprotein receptors (LDLRs) and plays a pivotal role in LDLR degradation [McKenney JM et al. J Am Coll Cardiol 2012]. This article discusses outcomes on the low-density lipoprotein cholesterol-lowering effects of SAR236553/REGN727 (SAR236553), a highly specific, fully human monoclonal antibody to PCSK9 [Efficacy and Safety Evaluation of SAR236553 (REGN727) In Patients With Primary Hypercholesterolemia and LDL-Cholesterol on Stable Atorvastatin Therapy; NCT01288443].